These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3601092)

  • 1. Levodopa methyl ester treatment of Parkinson's disease.
    Juncos JL; Mouradian MM; Fabbrini G; Serrati C; Chase TN
    Neurology; 1987 Jul; 37(7):1242-5. PubMed ID: 3601092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
    Fabbrini G; Juncos J; Mouradian MM; Serrati C; Chase TN
    Ann Neurol; 1987 Apr; 21(4):370-6. PubMed ID: 3579222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-O-methyldopa and motor fluctuations in Parkinson's disease.
    Fabbrini G; Juncos JL; Mouradian MM; Serrati C; Chase TN
    Neurology; 1987 May; 37(5):856-9. PubMed ID: 3574690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluctuating parkinsonism: a pilot study of single afternoon dose of levodopa methyl ester.
    Stocchi F; Barbato L; Bramante L; Nordera G; Vacca L; Ruggieri S
    J Neurol; 1996 May; 243(5):377-80. PubMed ID: 8741076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.
    Mouradian MM; Juncos JL; Fabbrini G; Chase TN
    Ann Neurol; 1987 Oct; 22(4):475-9. PubMed ID: 3435068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nighttime levodopa infusions to treat motor fluctuations in advanced Parkinson's disease: preliminary observations.
    Sage JI; Mark MH
    Ann Neurol; 1991 Oct; 30(4):616-7. PubMed ID: 1789688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease.
    Stocchi F; Ruggieri S; Carta A; Ryatt J; Quinn N; Jenner P; Marsden CD; Agnoli A
    Mov Disord; 1992; 7(3):249-56. PubMed ID: 1620143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's disease.
    Steiger MJ; Stocchi F; Carta A; Ruggieri S; Agnoli A; Quinn NP; Marsden CD
    Clin Neuropharmacol; 1991 Jun; 14(3):241-4. PubMed ID: 2070364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data.
    Marion MH; Stocchi F; Quinn NP; Jenner P; Marsden CD
    Clin Neuropharmacol; 1986; 9(2):165-81. PubMed ID: 3708602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical efficacy of a single afternoon dose of levodopa methyl ester: a double-blind cross-over study versus placebo.
    Stocchi F; Barbato L; Bramante L; Bonamartini A; Ruggieri S
    Funct Neurol; 1994; 9(5):259-64. PubMed ID: 7750809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3-O-methyldopa and the response to levodopa in Parkinson's disease.
    Nutt JG; Woodward WR; Gancher ST; Merrick D
    Ann Neurol; 1987 Jun; 21(6):584-8. PubMed ID: 3606046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study.
    Stocchi F; Vacca L; Ruggieri S; Olanow CW
    Arch Neurol; 2005 Jun; 62(6):905-10. PubMed ID: 15956161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenetic studies of motor fluctuations in Parkinson's disease.
    Chase TN; Mouradian MM; Fabbrini G; Juncos JL
    J Neural Transm Suppl; 1988; 27():3-10. PubMed ID: 3042912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease.
    Olanow CW; Gauger LL; Cedarbaum JM
    Ann Neurol; 1991 May; 29(5):556-9. PubMed ID: 1859185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and effects of levodopa in advanced Parkinson's disease.
    Bredberg E; Tedroff J; Aquilonius SM; Paalzow L
    Eur J Clin Pharmacol; 1990; 39(4):385-9. PubMed ID: 2076722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.
    Mouradian MM; Heuser IJ; Baronti F; Chase TN
    Ann Neurol; 1990 Jan; 27(1):18-23. PubMed ID: 2301923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietary influences on the antiparkinsonian response to levodopa.
    Juncos JL; Fabbrini G; Mouradian MM; Serrati C; Chase TN
    Arch Neurol; 1987 Oct; 44(10):1003-5. PubMed ID: 3632369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
    Nutt JG; Carter JH; Lea ES; Woodward WR
    Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations.
    Hardie RJ; Malcolm SL; Lees AJ; Stern GM; Allen JG
    Br J Clin Pharmacol; 1986 Oct; 22(4):429-36. PubMed ID: 3533125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.